Illustrative image – not actual.
Drug firm Cipla will invest around Rs 590 crore to launch a manufacturing facility in South Africa for the production of bio-similars.
For this, a memorandum of understanding (MOU) between Cipla BioTec and Dube Tradeport Corporation will be signed.
The facility will manufacture bio-similar drugs made from living organisms that will be used in the treatment of cancer and other diseases. Construction is scheduled to start in early 2017, with full operations expected to commence in the third quarter of 2018.
